Literature DB >> 9815542

Blood group antigen A and flow cytometric analysis in resected early-stage non-small cell lung cancer.

S L Graziano1, A H Tatum, N J Gonchoroff, N B Newman, L J Kohman.   

Abstract

The loss of blood group antigen A on tumor tissue has been reported to be a strong adverse prognostic marker for patients with resected non-small cell lung cancer (NSCLC). Results have varied with respect to the prognostic significance of flow cytometric data. We sought to confirm the prognostic significance of blood group antigen A loss and flow cytometry in a large cohort of patients with early-stage NSCLC. Two hundred and sixty patients with surgically resected stage I (n = 193) and II (n = 67) NSCLC with at least a 5-year follow-up were identified. Using paraffin-embedded primary tumor, immunohistochemical stains for blood group antigen A were performed on 90 patients with blood type A or AB. The DNA index and percentage of cells in S phase were successfully obtained on 188 and 152 patients, respectively. The median survival time of the patients with primary tumors negative for blood group antigen A was 38 months (n = 36), compared with 98 months (n = 54) for those with antigen A-positive tumors (P < 0.01). The median disease-free survival times for antigen A-negative and -positive tumors were 26 months and 98 months, respectively (P < h 0.01). The median survival time of the patients with aneuploid tumors was 51 months (n = 131), compared with 50 months (n = 57) for those with diploid tumors (P = 0.42). The median survival time of the patients with S phase >8% was 44 months (n = 105), compared with 60 months (n = 47) for those with S phase </=8% (P = 0.18). Multivariate analysis showed that the loss of antigen A, higher N and T stages, and the presence of mucin predicted for poorer disease-free and overall survival. In the subgroup of patients with blood group A or AB, the loss of A antigen was the most powerful negative predictor of survival. Aneuploidy and percentage of cells in S phase were not of prognostic significance in this group of patients with resected stage I and II NSCLC. The value of blood group antigen A analysis needs to be evaluated in larger and prospective studies of early-stage NSCLC. Alteration of blood group antigen cell surface expression may represent an important marker for more aggressive biological and metastatic behavior in NSCLC.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9815542

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  12 in total

Review 1.  Simple sugars to complex disease--mucin-type O-glycans in cancer.

Authors:  Matthew R Kudelka; Tongzhong Ju; Jamie Heimburg-Molinaro; Richard D Cummings
Journal:  Adv Cancer Res       Date:  2015-02-07       Impact factor: 6.242

2.  Prognostic significance of mucin and p53 expression in stage IB non-small cell lung cancer: a laboratory companion study to CALGB 9633.

Authors:  Stephen L Graziano; Lin Gu; Xiaofei Wang; Arthur H Tatum; Robin T Vollmer; Gary M Strauss; Robert Kratzke; Arkadiusz Z Dudek; Everett E Vokes; Mark R Green
Journal:  J Thorac Oncol       Date:  2010-06       Impact factor: 15.609

3.  A relationship between ABO blood groups and clinicopathologic characteristics of patients with gastric adenocarcinoma in China.

Authors:  Miao-Zhen Qiu; Dong-Sheng Zhang; Dan-Yun Ruan; Hui-Yan Luo; Zhi-Qiang Wang; Zhi-Wei Zhou; Feng-Hua Wang; Yu-Hong Li; Rui-Hua Xu
Journal:  Med Oncol       Date:  2010-11-04       Impact factor: 3.064

4.  Prognostic value of ABO blood group in patients with renal cell carcinoma: single-institution results from a large cohort.

Authors:  Chunwoo Lee; Dalsan You; Mooyoung Sohn; In Gab Jeong; Cheryn Song; Taekmin Kwon; Bumsik Hong; Jun Hyuk Hong; Hanjong Ahn; Choung-Soo Kim
Journal:  J Cancer Res Clin Oncol       Date:  2015-02-17       Impact factor: 4.553

5.  Do blood groups have effect on prognosis of patients undergoing radical cystectomy?

Authors:  Evren Süer; Cihat Özcan; Ilker Gökçe; Ömer Gülpınar; Cağatay Göğüş; Kadir Türkölmez; Sümer Baltacı; Yaşar Bedük
Journal:  Int Urol Nephrol       Date:  2014-03-28       Impact factor: 2.370

6.  Relationship between ABO blood group and clinicopathological factors and their effect on the survival of Japanese patients with esophageal squamous cell carcinoma.

Authors:  Fumiaki Shiratori; Hideaki Shimada; Satoshi Yajima; Takashi Suzuki; Yoko Oshima; Tatsuki Nanami; Masaaki Ito; Hironori Kaneko
Journal:  Surg Today       Date:  2016-12-27       Impact factor: 2.549

Review 7.  Tumor galectinology: insights into the complex network of a family of endogenous lectins.

Authors:  Harald Lahm; Sabine André; Andreas Hoeflich; Herbert Kaltner; Hans-Christian Siebert; Bernard Sordat; Claus-Wilhelm von der Lieth; Eckhard Wolf; Hans-Joachim Gabius
Journal:  Glycoconj J       Date:  2004       Impact factor: 2.916

Review 8.  The prognostic value of ABO blood group in cancer patients.

Authors:  Massimo Franchini; Giancarlo M Liumbruno; Giuseppe Lippi
Journal:  Blood Transfus       Date:  2015-11-06       Impact factor: 3.443

9.  Aneuploidy and prognosis of non-small-cell lung cancer: a meta-analysis of published data.

Authors:  D Choma; J P Daurès; X Quantin; J L Pujol
Journal:  Br J Cancer       Date:  2001-07-06       Impact factor: 7.640

10.  Prognostic role of the ABO blood types in Chinese patients with curatively resected non-small cell lung cancer: a retrospective analysis of 1601 cases at a single cancer center.

Authors:  Ning Li; Miao Xu; Chao-Feng Li; Wei Ou; Bao-Xiao Wang; Song-Liang Zhang; Peng-Fei Xu; Cheng Yuan; Qun-Ai Huang; Si-Yu Wang
Journal:  Chin J Cancer       Date:  2015-09-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.